Skip to search formSkip to main contentSkip to account menu

0.4 ML darbepoetin alfa 0.5 MG/ML Prefilled Syringe [Aranesp]

Known as: Aranesp 200 MCG in 0.4 ML Prefilled Syringe, Aranesp 0.2 MG per 0.4 ML Prefilled Syringe, DARBEPOETIN ALFA 200 ug in 0.4 mL SUBCUTANEOUS INJECTION, SOLUTION [ARANESP] 
National Institutes of Health

Related topics

Related topics

7 relations
AranespPolysorbate 80Prefilled SyringeSODIUM PHOSPHATE, DIBASIC, ANHYDROUS

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
USE OF DARBEPOETIN ALFA (ARANESP®) FOR ANEMIA TREATMENT IN CHILDREN WITH CHRONIC KIDNEY DISEASE – CLINICAL EXPERIENCE OF BULGARIAN PEDIATRIC GROUP
Darbepoetin alfa (DA) is indicated for treatment of symptomatic anemia related to chronic kidney disease (CKD) in adult and… 
2013
2013
Validation and implementation of MAIIA columns into routine analysis of urinary EPO screening
MAIIA Diagnostics have developed an EPO purification kit, using immunoaffinity columns (IAC), for rapid purification and… 
2011
2011
Docelowe stężenie hemoglobiny w przypadku leczenia czynnikami pobudzającymi erytropoezę - stanowisko przyjęte przez European Renal Best Practice po opublikowaniu wyników badania Trial to Reduce…
European Renal Best Practice (ERBP) wydane przez European Renal Association-European Dialysis and Transplant Association… 
2007
2007
198: The use of recombinant human erythropoietin (rHuEpo) after reduced intensity conditioning (RIC) allogeneic hematopoietic peripheral blood stem cell transplantation (ASCT) reduces red blood cell…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)